In this study, we identified MAGEA3 as a gene associated with primary resistance to bevacizumab in CRC patients using sequencing data, and further investigated its role in bevacizumab resistance and its impact on prognosis in CRC patients. The gene discussed is MAGEA3; the disease is colorectal carcinoma.